Hepatitis C virus particles, vaccines, compositions and methods related thereto
This disclosure relates to viral particles and nucleic acids encoding an HCV envelope glycoprotein 2 containing a mutation. Viral particles can be created and administered to a subject to illicit an immune response.
1. A full length hepatitis C virus envelope glycoprotein 2 wherein cysteine corresponding to amino acid position 505 of SEQ ID NO: 35 is substituted with alanine.
2. A purified virus particle comprising a hepatitis C virus envelope glycoprotein 2 as in claim 1 .
3. A nucleic acid encoding hepatitis C virus envelope glycoprotein 2 of claim 1 .
4. The nucleic acid of claim 3 , further comprising NS3, 4A, 4B, NS5A, NS5B genes from JFH genotype 2a strain of HCV.
5. The nucleic acid of claim 3 , further comprising C, E1, p7, and NS2, genes from J6 strain of HCV.
6. A recombinant hepatitis C virus comprising genes sufficient to produce viral particle and a nucleic acid encoding a full length hepatitis C virus envelope glycoprotein 2 wherein cysteine corresponding to amino acid position 505 of SEQ ID NO: 35 is substituted with alanine.
7. An immunogenic composition comprising a virus particle wherein the virus particle comprises full length hepatitis C virus envelope protein 2 wherein cysteine corresponding to amino acid position 505 of SEO ID NO: 35 is substituted with alanine.
8. The immunogenic composition of claim 7 , further comprising an adjuvant.
9. The immunogenic composition of claim 8 , wherein the adjuvant comprises an aluminum salt, oil, liposome, lipopsaccharide, squalene, polyoxylethylene sorbitan, sorbitan trioleate, a flagellin, double stranded RNA, or nucleic acid with an unmethylated CpG motif.
10. A pharmaceutical composition comprising a full length hepatitis C virus envelope glycoprotein 2 wherein cysteine corresponding to amino acid position 505 of SEO ID NO: 35 is substituted with alanine.